| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenues: | ||||||
Total revenue | ||||||
9,481 | 9,656 | 5,319 | 6,482 | - | - | |
Research premium and grant revenue | ||||||
- | - | - | - | 3,767 | 2,398 | |
Operating expenses: | ||||||
Cost of product sales | ||||||
70 | - | - | - | - | - | |
Research and development expenses | ||||||
26,415 | 82,288 | 49,615 | 47,994 | 23,604 | - | |
Selling, general and administrative expenses | ||||||
62,485 | 41,743 | 29,472 | - | - | - | |
Total operating expenses | ||||||
88,970 | 124,031 | 79,087 | - | - | - | |
Research and development | ||||||
- | - | - | - | - | 9,355 | |
General and administrative | ||||||
- | - | - | 13,535 | 7,921 | 3,739 | |
Total operating expenses | ||||||
- | - | - | 61,529 | 31,525 | 13,094 | |
Loss from operations | ||||||
-79,489 | -114,375 | -73,768 | -55,047 | -27,758 | -10,696 | |
Other income (expense): | ||||||
Other income (expense), net | ||||||
215 | -272 | 492 | -783 | - | - | |
Other income (expense), net | ||||||
- | - | - | - | 2,427 | -524 | |
Interest income | ||||||
255 | 49 | 318 | 343 | 14 | 2 | |
Interest expense | ||||||
3,644 | 133 | 43 | 75 | 22,092 | 2,910 | |
Loss before income taxes | ||||||
-82,663 | -114,731 | -73,001 | -55,562 | -47,409 | - | |
Loss before income taxes | ||||||
- | - | - | - | - | -14,128 | |
Income tax expense | ||||||
101 | 49 | 1,355 | -672 | -445 | 94 | |
Net loss | ||||||
-82,764 | -114,780 | -74,356 | -54,890 | -46,964 | -14,222 | |
Other comprehensive income (loss), net of tax | ||||||
Exchange differences on translating foreign operations | ||||||
- | - | - | - | 2,026 | 3,374 | |
Unrealized losses on available-for-sale securities | ||||||
- | - | -26 | -18 | -68 | - | |
Reclassification to net income | ||||||
- | - | -43 | -68 | - | - | |
Other comprehensive income, net of tax | ||||||
- | - | 17 | 50 | 1,958 | - | |
Other comprehensive income (loss), net of tax | ||||||
- | - | - | - | - | 3,374 | |
Comprehensive loss | ||||||
-82,764 | -114,780 | -74,339 | -54,840 | -45,006 | -10,848 | |
Loss per share | ||||||
Basic and Diluted ($ per share) | ||||||
-1.12 | -2.26 | -2.49 | -2.56 | -4.80 | - | |
Basic (in dollars per share) | ||||||
- | - | - | - | - | -44.39 | |
Diluted (in dollars per share) | ||||||
- | - | - | - | - | -44.39 | |
Weighted average number of shares: | ||||||
Basic and Diluted | ||||||
74,199 | 50,795 | 29,830 | 21,478 | 10,583 | - | |
Basic (in shares) | ||||||
- | - | - | - | - | 324 | |
Diluted (in shares) | ||||||
- | - | - | - | - | 324 | |
Product revenue, net | ||||||
Total revenue | ||||||
1,538 | - | - | - | - | - | |
Collaboration revenue | ||||||
Total revenue | ||||||
6,210 | 6,500 | - | - | - | - | |
Research premium and grant revenue | ||||||
Total revenue | ||||||
1,733 | 3,156 | 5,319 | 6,482 | - | - | |